Biomarkers: The useful and the not so useful an assessment of molecular prognostic markers for Cutaneous melanoma

Journal of Investigative Dermatology

Volumn 130, Issue 8, 2010, Pages 1971-1987

  Gould Rothberg, Bonnie E ^a   Rimm, David L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; BETA CATENIN; BETA3 INTEGRIN; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CD51 ANTIGEN; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FRIZZLED PROTEIN; GROWTH DIFFERENTIATION FACTOR 15; HEAT SHOCK PROTEIN 90; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; MYC PROTEIN; NERVE GROWTH FACTOR; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN MLH1; PROTEIN S100B; SECURIN; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 4; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR EZH2; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA2; TUMOR MARKER; UNINDEXED DRUG; UVOMORULIN; VASCULOTROPIN A;

CANCER INVASION; CELL ADHESION; CROSS-SECTIONAL STUDY; HUMAN; IMMUNOCOMPETENCE; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TUMOR GROWTH; TUMOR VOLUME;

EID: 77954760173     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2010.149     Document Type: Article

References (257)

1. Adnane L, Trail PA, Taylor I, et al. (2005) Sorafenib (BAY 43-9006, Nexavar((R))), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/ PDGFR in tumor vasculature. Methods En-zymol 407:597-612
2. Ahrens T, Assmann V, Fieber C, et al. (2001) CD44 is the principal mediator of hyaluronic-acid-induced melanoma cell proliferation. J Invest Dermatol 116:93-101
3. Alonso SR, Ortiz P, Pollan M et al. (2004) Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am J Pathol 164:193-203
4. Amersi FF, Terando AM, Goto Y et al. (2008) Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine. Clin Cancer Res 14:638-645
5. Andersen K, Nesland JM, Holm R et al. (2004) Expression of S100A4 combined with reduced E-cadherin expression predicts patient outcome in malignant melanoma. Mod Pathol 17:990-997
6. Antonescu CR, Busam KJ, Francone TD et al. (2007) L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer 121:257-264
7. Arndt S, Bosserhoff AK (2006) TANGO is a tumor suppressor of malignant melanoma. Int J Cancer 119:2812-2820
8. Ascierto PA, Kirkwood JM (2008) Adjuvant therapy of melanoma with interferon: lessons of the past decade. J Transl Med 6:62
9. Bachmann IM, Halvorsen OJ, Collett K et al. (2006) EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 24:268-273
10. Bachmann IM, Ladstein RG, Straume O et al. (2008) Tumor necrosis is associated with increased alphavbeta3 integrin expression and poor prognosis in nodular cutaneous melanomas. BMC Cancer 8:362
11. Bachmann IM, Straume O, Akslen LA (2004) Altered expression of cell cycle regulators Cyclin D1, p14, p16, CDK4 and Rb in nodular melanomas. Int JOncol 25:1559-1565
12. Bachmann IM, Straume O, Puntervoll HE et al. (2005) Importance of P-cadherin, beta-cate-nin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. Clin Cancer Res 11:8606-8614
13. Bagnato A, Rosano L, Spinella F et al. (2004) Endothelin B receptor blockade inhibits dynamics of cell interactions and communications in melanoma cell progression. Cancer Res 64:1436-1443 (Pubitemid 38235614)
14. Balch CM, Soong SJ, Gershenwald JE, et al. (2001) Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19:3622-3634
15. Baldi A, De Luca A, Morini M et al. (2002) The HtrA1 serine protease is down-regulated during human melanoma progression and represses growth of metastatic melanoma cells. Oncogene 21:6684-6688
16. Baldi A, Lombardi D, Russo P et al. (2005) Ferritin contributes to melanoma progression by modulating cell growth and sensitivity to oxidative stress. Clin Cancer Res 11:3175-3183
17. Baldi A, Santini D, Battista T et al. (2001) Expression of AP-2 transcription factor and of its downstream target genes c-kit, E-cadherin and p21 in human cutaneous melanoma. J Cell Biochem 83:364-372
18. Baldi A, Santini D, Russo P et al. (2004) Analysis of APAF-1 expression in human cutaneous melanoma progression. Exp Dermatol 13:93-97
19. Banfalvi T, Udvarhelyi N, Orosz Z et al. (2003) Heterogenous S-100B protein expression patterns in malignant melanoma and association with serum protein levels. Oncology 64:374-379 (Pubitemid 36682951)
20. Barrow C, Browning J, MacGregor D et al. (2006) Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res 12:764-771
21. Batinac T, Hadzisejdic I, Brumini G et al. (2007) Expression of cell cycle and apoptosis regulatory proteins and telomerase in mela-nocitic lesions. Coll Antropol 31(Suppl 1):17-22
22. Bayer-Garner IB, Hough AJ Jr, Smoller BR (1999) Vascular endothelial growth factor expression in malignant melanoma: prognostic versus diagnostic usefulness. Mod Patho 12:770-774
23. Beane J, Spira A, Lenburg ME (2009) Clinical impact of high-throughput gene expression studies in lung cancer. J Thorac Oncol 4:109-118
24. Becker B, Multhoff G, Farkas B et al. (2004) Induction of Hsp90 protein expression in malignant melanomas and melanoma me-tastases. Exp Dermatol 13:27-32
25. Bertucci F, Pages C, Finetti P et al. (2007) Gene expression profiling of human melanoma cell lines with distinct metastatic potential identifies new progression markers. Antic-ancer Res 27:3441-3449
26. Bilalovic N, Sandstad B, Golouh R et al. (2004) CD10 protein expression in tumor and stromal cells of malignant melanoma is associated with tumor progression. Mod Pathol 17:1251-1258
27. Birck A, Kirkin AF, Zeuthen J et al. (1999) Expression of basic fibroblast growth factor and vascular endothelial growth factor in primary and metastatic melanoma from the same patients. Melanoma Res 9:375-381
28. Bishop PW, Menasce LP, Yates AJ et al. (1993) An immunophenotypic survey of malignant melanomas. Histopathology 23:159-166
29. Bittner M, Meltzer P, Chen Y et al. (2000) Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406:536-540
30. Bodey B, Bodey BJr, Siegel SE, et al. (2001) Matrix metalloproteinase expression in malignant melanomas: tumor-extracellular matrix interactions in invasion and metastasis. In Vivo15:57-64
31. Boni R, Bantschapp O, Muller B et al. (1998) c-myc is not useful as prognostic immuno-histochemical marker in cutaneous melanoma. Dermatology 196:288-291
32. Boni R, Heizmann CW, Doguoglu A, et al. (1997) Ca(2+)-binding proteins S100A6 and S100B in primary cutaneous melanoma. J Cutan Pathol 24:76-80
33. Boone B, Blokx W, De Bacquer D et al. (2008) The role of VEGF-C staining in predicting regional metastasis in melanoma. Virchows Arch 453:257-65
34. Arch 453:257-65 Boyle GM, Pedley J, Martyn AC et al. (2009) Macrophage inhibitory cytokine-1 is over-expressed in malignant melanoma and is associated with tumorigenicity. J Invest Dermatol 129:383-391
35. Brychtova S, Bezdekova M, Brychta T, et al. (2008) The role of vascular endothelial growth factors and their receptors in malignant melanomas. Neoplasma 55:273-279
36. Brychtova S, Fiuraskova M, Brychta T et al. (2005) [The role of intermedial filament nestin in malignant melanoma progression]. Cesk Patol 41:143-145
37. Byrd-Miles K, Toombs EL, Peck GL (2007) Skin cancer in individuals of African, Asian, Latin-American, and American-Indian descent: differences in incidence, clinical presentation, and survival compared to Caucasians. J Drugs Dermatol 6:10-16
38. Camp RL, Neumeister V, Rimm DL (2008) A decade of tissue microarrays: progress in the discovery and validation of cancer biomar-kers. J Clin Oncol 26:5630-5637
39. Carrel S, Zografos L, Schreyer M et al. (1993) Expression of CALLA/CD10 on human melanoma cells. Melanoma Res 3:319-323 (Pubitemid 23329693)
40. Chakravarti N, Lotan R, Diwan AH et al. (2007) Decreased expression of retinoid receptors in melanoma: entailment in tumorigenesis and prognosis. Clin Cancer Res 13:4817-4824
41. Chen X, Lin J, Kanekura T et al. (2006) A small interfering CD147-targeting RNA inhibited the proliferation, invasiveness, and meta-static activity of malignant melanoma. Cancer Res 66:11323-11330
42. Chien AJ, Moore EC, Lonsdorf AS et al. (2009) Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc Natl Acad Sci USA 106:1193-1198
43. Cho KH, Hashimoto K, Taniguchi Y, et al. (1990) Immunohistochemical study of melanocytic nevus and malignant melanoma with monoclonal antibodies against S-100 subunits. Cancer 66:765-771
44. Chwirot BW, Kuzbicki L (2007) Cyclooxygenase-2 (COX-2): first immunohistochemical mar-ker distinguishing early cutaneous melanomas from benign melanocytic skin tumours. Melanoma Res 17:139-145
45. Ciotti P, Pesce GP, Cafiero F et al. (1999) Intercellular adhesion molecule-1 (ICAM-1) and granulocyte-macrophage colony stimulating factor (GM-CSF) co-expression in cutaneous malignant melanoma lesions. Melanoma Res 9:253-260
46. Cohen C, DeRose PB, Campbell WG et al. (1990) Estrogen receptor status in malignant melanoma. Am J Dermatopathol 12:562-564
47. Cohn ML, Goncharuk VN, Diwan AH et al. (2005) Loss of claudin-1 expression in tumor-associated vessels correlates with acquisition of metastatic phenotype in melanocytic neoplasms. J Cutan Pathol 32:533-536
48. Corte MD, Gonzalez LO, Corte MG et al. (2005) Collagenase-3 (MMP-13) expression in cutaneous malignant melanoma. Int J Biol Markers 20:242-248
49. Cruz J, Reis-Filho JS, Silva P et al. (2003) Expression of c-met tyrosine kinase receptor is biologically and prognostically relevant for primary cutaneous malignant melanomas. Oncology 65:72-82
50. Da Forno PD, Pringle JH, Hutchinson P et al. (2008) WNT5A expression increases during melanoma progression and correlates with outcome. Clin Cancer Res 14:5825-5832
51. Dai DL, Makretsov N, Campos EI et al. (2003) Increased expression of integrin-linked kinase is correlated with melanoma progression and poor patient survival. Clin Cancer Res 9:4409-4414
52. Dai DL, Martinka M, Bush JA et al. (2004) Reduced Apaf-1 expression in human cutaneous melanomas. Br J Cancer 91:1089-1095 (Pubitemid 39336247)
53. Danen EH, Jansen KF, Van Kraats AA et al. (1995) Alpha v-integrins in human melanoma: gain of alpha v beta 3 and loss of alpha v beta 5 are related to tumor progression in situ but not to metastatic capacity of cell lines in nude mice. Int J Cancer 61:491-496
54. Danen EH, Ten Berge PJ, Van Muijen GN et al. (1994) Emergence of alpha 5 beta 1 fibro-nectin- and alpha v beta 3 vitronectin-receptor expression in melanocytic tumour progression. Histopathology 24:249-256
55. de Giorgi V, Mavilia C, Massi D et al. (2009) Estrogen receptor expression in cutaneous melanoma: a real-time reverse transcriptase-polymerase chain reaction and immunohis-tochemical study. Arch Dermatol 145:30-36
56. de Vries TJ, Smeets M, de Graaf R et al. (2001) Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group. J Pathol 193:13-20
57. Demirkesen C, Buyukpinarbasili N, Ramazanoglu R et al. (2006) The correlation of angiogen-esis with metastasis in primary cutaneous melanoma: a comparative analysis of micro-vessel density, expression of vascular en-dothelial growth factor and basic fibroblastic growth factor. Pathology 38:132-137
58. Demunter A, De Wolf-Peeters C, Degreef H et al. (2001) Expression of the endothelin-B receptor in pigment cell lesions of the skin. Evidence for its role as tumor progression marker in malignant melanoma. Virchows Arch 438:485-491
59. Demunter A, Libbrecht L, Degreef H et al. (2002) Loss of membranous expression of beta-catenin is associated with tumor progression in cutaneous melanoma and rarely caused by exon 3 mutations. Mod Pathol 15:454-461
60. Denkert C, Kobel M, Berger S et al. (2001) Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res 61:303-308
61. Denton KJ, Stretch JR, Gatter KC et al. (1992) A study of adhesion molecules as markers of progression in malignant melanoma. JPathol 167:187-191
62. Depasquale I, Thompson WD (2008) Prognosis in human melanoma: PAR-1 expression is superior to other coagulation components and VEGF. Histopathology 52:500-509
63. Dissanayake SK, Olkhanud PB, OConnell MP et al. (2008) Wnt5A regulates expression of tumor-associated antigens in melanoma via changes in signal transducers and activators of transcription 3 phosphorylation. Cancer Res 68:10205-10214
64. Dissemond J, Busch M, Kothen T et al. (2004) Differential downregulation of endoplasmic reticulum-residing chaperones calnexin and calreticulin in human metastatic melanoma. Cancer Lett 203:225-231
65. Dos Reis PP, Bharadwaj RR, Machado J et al. (2008) Claudin 1 overexpression increases invasion and is associated with aggressive histological features in oral squamous cell carcinoma. Cancer 113:3169-3180
66. Duffy MJ, McGowan PM, Gallagher WM (2008) Cancer invasion and metastasis: changing views. J Pathol 214:283-293
67. Easty DJ, Hill SP, Hsu MY et al. (1999) Up-regulation of ephrin-A1 during melanoma progression. Int J Cancer 84:494-501
68. Ehrmann J, Kolar Z, Mokry J (2005) Nestin as a diagnostic and prognostic marker: immuno-histochemical analysis of its expression in different tumours. J Clin Pathol 58:222-223
69. Einspahr JG, Thomas TL, Saboda K et al. (2007) Expression of vascular endothelial growth factor in early cutaneous melanocytic lesion progression. Cancer 110:2519-2527
70. Ekmekcioglu S, Ellerhorst JA, Mumm JB et al. (2003) Negative association of melanoma differentiation-associated gene (mda-7) and inducible nitric oxide synthase (iNOS) in human melanoma: MDA-7 regulates iNOS expression in melanoma cells. Mol Cancer Ther 2:9-17
71. Eliopoulos P, Mohammed MQ, Henry K et al. (2002) Overexpression of HER-2 in thick melanoma. Melanoma Res 12:139-145
72. Emanuel PO, Phelps RG, Mudgil A et al. (2008) Immunohistochemical detection of XIAP in melanoma. J Cutan Pathol 35:292-297
73. Engl T, Relja B, Marian D et al. (2006) CXCR4 chemokine receptor mediates prostate tumor cell adhesion through alpha5 and beta3 integrins. Neoplasia 8:290-301
74. Erhard H, Rietveld FJ, van Altena MC, et al. (1997) Transition of horizontal to vertical growth phase melanoma is accompanied by induction of vascular endothelial growth factor expression and angiogenesis. Melanoma Res 7(Suppl 2):S19-26
75. Fecker LF, Geilen CC, Tchernev G et al. (2006) Loss of proapoptotic Bcl-2-related multido-main proteins in primary melanomas is associated with poor prognosis. J Invest Dermatol 126:1366-1371
76. Ferrier CM, Suciu S, van Geloof WL et al. (2000) High tPA-expression in primary melanoma of the limb correlates with good prognosis. Br J Cancer 83:1351-1359
77. Fink-Puches R, Pilarski P, Schmidbauer U et al. (2001) No evidence for c-erbB-2 overexpres-sion in cutaneous melanoma. Anticancer Res 21:2793-2795
78. Fiuraskova M, Brychtova S, Sedlakova E et al. (2005) Molecular changes in PDEGF and bFGF in malignant melanomas in relation to the stromal microenvironment. Anticancer Res 25:4299-4303
79. Florenes VA, Maelandsmo GM, Holm R et al. (2004) Expression of activated TrkA protein in melanocytic tumors: relationship to cell proliferation and clinical outcome. Am JClin Pathol 122:412-420
80. Fritzsche FR, Oelrich B, Johannsen M, et al. (2008) Claudin-1 protein expression is a prognostic marker of patient survival in renal cell carcinomas. Clin Cancer Res 14:7035-7042
81. Giatromanolaki A, Sivridis E, Kouskoukis C et al. (2003) Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Res 13:493-501
82. Giehl KA, Nagele U, Volkenandt M et al. (2007) Protein expression of melanocyte growth factors (bFGF, SCF) and their receptors (FGFR-1, c-kit) in nevi and melanoma. J Cutan Pathol 34:7-14
83. Gilaberte Y, Vera J, Coscojuela C et al. (2007) [Expression of galanin in melanocytic tumors]. Actas Dermosifiliogr 98:24-34
84. Gimotty PA, Botbyl J, Soong SJ et al. (2005) A population-based validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 23:8065-8075
85. Gimotty PA, Elder DE, Fraker DL et al. (2007) Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol 25:1129-1134
86. Gould Rothberg BE, Bracken MB, Rimm DL (2009) Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 101:452-474
87. Goulet AC, Einsphar JG, Alberts DS et al. (2003) Analysis of cyclooxygenase 2 (COX-2) expression during malignant melanoma prgression. Cancer Biol Ther 2:713-718
88. Granovsky AE, Rosner MR (2008) Raf kinase inhibitory protein: a signal transduction modulator and metastasis suppressor. Cell Res 18:452-457
89. Guarino M, Rubino B, Ballabio G (2007) The role of epithelial-mesenchymal transition in cancer pathology. Pathology 39:305-318
90. Gutman M, Even-Sapir E, Merimsky O et al. (2002) The role of interleukin-8 in the initiation and progression of human cutaneous melanoma. Anticancer Res 22:3395-3398
91. Hafner C, Bataille F, Meyer S et al. (2003) Loss of EphB6 expression in metastatic melanoma. IntJ Oncol 23:1553-1559
92. Hagen EC, Vennegoor C, Schlingemann RO et al. (1986) Correlation of histopathological characteristics with staining patterns in human melanoma assessed by (monoclonal) anti-bodies reactive on paraffin sections. Histo- pathology 10:689-700
93. Han ZD, Bi XC, Qin WJ et al. (2008a) CD147 expression indicates unfavourable prognosis in prostate cancer. Pathol Oncol Res 2:2
94. Han ZD, He HC, Bi XC et al. (2008b) Expression and clinical significance of CD147 in genitourinary carcinomas. J Surg Res 10:10
95. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70
96. Haritopoulos KN, Lazaris AC, Kavantzas N et al. (2003) ICAM-1 and beta(3) integrin immu-noexpression in malignant melanoma cells: can they be used as additional predictors? APMIS 111:421-429
97. Hazarika P, McCarty MF, Prieto VG et al. (2004) Up-regulation of Flotillin-2 is associated with melanoma progression and modulates expression of the thrombin receptor protease activated receptor 1. Cancer Res 64:7361-7369
98. Hensley C, Spitzler S, McAlpine BE et al. (1998) In vivo human melanoma cytokine production: inverse correlation of GM-CSF production with tumor depth. Exp Dermatol 7:335-341
99. Hess AR, Postovit LM, Margaryan NV, et al. (2005) Focal adhesion kinase promotes the aggressive melanoma phenotype. Cancer Res 65:9851-9860
100. Hieken TJ, Farolan M, Ronan SG et al. (1996) Beta3 integrin expression in melanoma predicts subsequent metastasis. J Surg Res 63:169-173
101. Hieken TJ, Ronan SG, Farolan M et al. (1999) Molecular prognostic markers in intermediate-thickness cutaneous malignant melanoma. Cancer 85:375-382
102. Hofmann UB, Westphal JR, Zendman AJ et al. (2000) Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression. J Pathol 191:245-256
103. Huang FJ, Steeg PS, Price JE et al. (2008) Molecular basis for the critical role of suppressor of cytokine signaling-1 in melanoma brain metastasis. Cancer Res 68:9634-9642
104. Hussein MR, Roggero E, Sudilovsky EC et al. (2001) Alterations of mismatch repair protein expression in benign melanocytic nevi, melanocytic dysplastic nevi, and cutaneous malignant melanomas. Am J Dermatopathol 23:308-314
105. Ilmonen S, Vaheri A, Asko-Seljavaara S et al. (2005) Ezrin in primary cutaneous melanoma. Mod Pathol 18:503-510
106. Innocenzi D, Alo PL, Balzani A, et al. (2003) Fatty acid synthase expression in melanoma. J Cutan Pathol 30:23-28
107. Innominato PF, Libbrecht L, van den Oord JJ (2001) Expression of neurotrophins and their receptors in pigment cell lesions of the skin. J Pathol 194:95-100
108. Jemal A, Siegel R, Ward E et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71-96
109. Jezierska A, Motyl T (2009) Matrix metalloprotei-nase-2 involvement in breast cancer progression: a mini-review. Med Sci Monit 15:RA32-40
110. Johnson JP, Stade BG, Holzmann B et al. (1989) De novo expression of intercellular-adhesion molecule 1 in melanoma correlates with increased risk of metastasis. Proc Natl Acad Sci USA 86:641-644
111. Jorgensen K, Davidson B, Florenes VA (2006) Activation of c-jun N-terminal kinase is associated with cell proliferation and shorter relapse-free period in superficial spreading malignant melanoma. Mod Pathol 19:1446-1455
112. Jorgensen K, Holm R, Maelandsmo GM et al. (2003) Expression of activated extracellular signal-regulated kinases 1/2 in malignant melanomas: relationship with clinical outcome. Clin Cancer Res 9:5325-5331
113. Joyce T, Cantarella D, Isella C et al. (2009) A molecular signature for epithelial to me-senchymal transition in a human colon cancer cell system is revealed by large-scale microarray analysis. Clin Exp Metastasis 2:2
114. Kalogeraki A, Garbagnati F, Darivianaki K et al. (2006) HSP-70, C-myc and HLA-DR expression in patients with cutaneous malignant melanoma metastatic in lymph nodes. Antic-ancer Res 26:3551-3554
115. Kanitakis J, Narvaez D, Claudy A (2002) Differential expression of the CD10 antigen (neutral endopeptidase) in primary versus metastatic malignant melanomas of the skin. Melanoma Res 12:241-244
116. Karst AM, Dai DL, Martinka M et al. (2005) PUMA expression is significantly reduced in human cutaneous melanomas. Oncogene 24:1111-1116
117. Kielhorn E, Provost E, Olsen D et al. (2003) Tissue microarray-based analysis shows phospho-beta-catenin expression in malignant melanoma is associated with poor outcome. Int J Cancer 103:652-656
118. Kim SH, Gunnery S, Choe JK et al. (2002) Neoplastic progression in melanoma and colon cancer is associated with increased expression and activity of the interferon-inducible protein kinase, PKR. Oncogene 21:8741-8748
119. Klein WM, Wu BP, Zhao S, et al. (2007) Increased expression of stem cell markers in malignant melanoma. Mod Pathol 20:102-107
120. Kluger HM, DiVito K, Berger AJ et al. (2004) Her2/neu is not a commonly expressed therapeutic target in melanoma-a large cohort tissue microarray study. Melanoma Res 14:207-210
121. Kononen J, Bubendorf L, Kallioniemi A et al. (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4:844-847
122. Korabiowska M, Brinck U, Mirecka J et al. (1995) Antigen Ki-67 and c-myc oncogene as related to histoclinical parameters in pig-mented skin lesions. In Vivo 9:433-438
123. Korabiowska M, Schlott T, Siems N et al. (2004) Analysis of adenomatous polyposis coli gene expression, APC locus-microsatellite in-stability and APC promoter methylation in the progression of melanocytic tumours. Mod Pathol 17:1539-1544
124. Kreizenbeck GM, Berger AJ, Subtil A et al. (2008) Prognostic significance of cadherin-based adhesion molecules in cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev 17:949-958
125. Krengel S, Groteluschen F, Bartsch S et al. (2004) Cadherin expression pattern in melanocytic tumors more likely depends on the melano-cyte environment than on tumor cell prgression. J Cutan Pathol 31:1-7
126. Kuivanen T, Ahokas K, Virolainen S et al. (2005) MMP-21 is upregulated at early stages of melanoma progression but disappears with more aggressive phenotype. Virchows Arch 447:954-960
127. Kuphal S, Lodermeyer S, Bataille F et al. (2006a) Expression of Dickkopf genes is strongly reduced in malignant melanoma. Oncogene 25:5027-5036
128. Kuphal S, Wallner S, Schimanski CC, et al. (2006b) Expression of Hugl-1 is strongly reduced in malignant melanoma. Oncogene 25:103-110 (Pubitemid 43050008)
129. Kurschat P, Wickenhauser C, Groth W et al. (2002) Identification of activated matrix metalloproteinase-2 (MMP-2) as the main gelatinolytic enzyme in malignant melanoma by in situ zymography. J Pathol 197:179-187
130. Kuzbicki L, Gajo B, Chwirot BW (2006a) Different expression of lysosome-associated membrane protein-1 in human melanomas and benign melanocytic lesions. Melanoma Res 16:235-243 (Pubitemid 44085097)
131. Kuzbicki L, Sarnecka A, Chwirot BW (2006b) Expression of cyclooxygenase-2 in benign naevi and during human cutaneous melanoma progression. Melanoma Res16:29-36
132. Lahav R (2005) Endothelin receptor B is required for the expansion of melanocyte precursors and malignant melanoma. Int J Dev Biol 49:173-180
133. Lahav R, Suva ML, Rimoldi D et al. (2004) Endothelin receptor B inhibition triggers apoptosis and enhances angiogenesis in melanomas. Cancer Res 64:8945-8953
134. Lee C, Ramirez JA, Guitart J et al. (2008a) Expression of cyclooxygenase-2 and peroxi-some proliferator-activated receptor gamma during malignant melanoma progression. J Cutan Pathol 35:989-994
135. Lee HJ, Wall B, Chen S (2008b) G-protein-coupled receptors and melanoma. Pigment Cell Melanoma Res 21:415-428
136. Lefevre G, Babchia N, Calipel A et al. (2009) Activation of the FGF2/FGFR1 autocrine loop for cell proliferation and survival in uveal melanoma cells. Invest Ophthalmol Vis Sci 50:1047-1057
137. Leotlela PD, Wade MS, Duray PH et al. (2007) Claudin-1 overexpression in melanoma is regulated by PKC and contributes to melanoma cell motility. Oncogene 26:3846-3856
138. Li J, Martinka M, Li G (2008) Role of ING4 in human melanoma cell migration, invasion and patient survival. Carcinogenesis 29:1373-1379
139. Li Z, Metze D, Nashan D et al. (2004) Expression of SOCS-1, suppressor of cytokine signalling-1, in human melanoma. J Invest Dermatol 123:737-745
140. Lowney JK, Boucher LD, Swanson PE et al. (1999) Interferon regulatory factor-1 and -2 expression in human melanoma specimens. Ann Surg Oncol 6:604-608
141. Maelandsmo GM, Holm R, Nesland JM et al. (2003) Reduced beta-catenin expression in the cytoplasm of advanced-stage superficial spreading malignant melanoma. Clin Cancer Res 9:3383-3388
142. Marcoval J, Moreno A, Graells J et al. (1997) Angiogenesis and malignant melanoma. An-giogenesis is related to the development of vertical (tumorigenic) growth phase. J Cutan Pathol 24:212-218
143. Massi D, Naldini A, Ardinghi C et al. (2005) Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma. Hum Pathol 36:676-685
144. McCarthy MM, Pick E, Kluger Y et al. (2008) HSP90 as a marker of progression in melanoma. Ann Oncol 19:590-594
145. McDonald PC, Fielding AB, Dedhar S (2008) Integrin-linked kinase-essential roles in physiology and cancer biology. J Cell Sci 121:3121-32
146. McHugh JB, Fullen DR, Ma L et al. (2007) Expression of polycomb group protein EZH2 in nevi and melanoma. JCutan Pathol 34:597-600
147. McShane LM, Altman DG, Sauerbrei W et al. (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97:1180-1184 (Pubitemid 41258223)
148. Mirecka J, Korabiowska M, Schauer A (1995) Comparative distribution of S-100 protein and antigen HMB-45 in various types of melanomas and naevi. Pol J Pathol 46:167-172
149. Mnich CD, Hoek KS, Oberholzer PA, et al. (2007) Reduced pSmad2 immunodetection correlates with increased primary melanoma thickness. Melanoma Res 17:131-136
150. Monteagudo C, Martin JM, Jorda E et al. (2007) CXCR3 chemokine receptor immunoreactiv-ity in primary cutaneous malignant melanoma: correlation with clinicopathologic prognostic factors. J Clin Pathol 60:596-599
151. Moretti S, Pinzi C, Berti E et al. (1997) In situ expression of transforming growth factor beta is associated with melanoma progression and correlates with Ki67, HLA-DR and beta 3 integrin expression. Melanoma Res 7:313-321
152. Moretti S, Pinzi C, Spallanzani A et al. (1999) Immunohistochemical evidence of cytokine networks during progression of human mel-anocytic lesions. Int J Cancer 84:160-168
153. Mouawad R, Spano JP, Comperat E et al. (2009) Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: correlation with clinical parameters and outcome. Eur J Cancer 45:1407-1414
154. Murry BP, Greiter-Wilke A, Paulsen DP et al. (2005) Selective heparanase localization in malignant melanoma. Int JOncol 26:345-352
155. Nabeshima K, Iwasaki H, Koga K et al. (2006) Emmprin (basigin/CD147): matrix metallo-proteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression. Pathol Int 56:359-367
156. Natali P, Nicotra MR, Cavaliere R et al. (1990) Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. Cancer Res 50:1271-1278
157. Natali PG, Hamby CV, Felding-Habermann B et al. (1997) Clinical significance of alpha(v)-beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions. Cancer Res 57:1554-1560
158. Natali PG, Nicotra MR, Cavaliere R et al. (1991) Tumor progression in human malignant melanoma is associated with changes in alpha 6/beta 1 laminin receptor. Int JCancer 49:168-172
159. Natali PG, Nicotra MR, Di Filippo F, et al. (1995) Expression of fibronectin, fibronectin iso-forms and integrin receptors in melanocytic lesions. Br J Cancer 71:1243-1247
160. Natali PG, Nicotra MR, Nuti M et al. (1988) Molecular profile, tissue distribution and prognostic evaluation of a human melanoma-carcinoma antigen recognized by the murine monoclonal antibody B1.1. Int JBiol Markers 3:211-220
161. Natali PG, Roberts JT, Difilippo F et al. (1987) Immunohistochemical detection of antigen in human primary and metastatic melanomas by the monoclonal antibody 140.240 and its possible prognostic significance. Cancer 59:55-63
162. Neto DS, Pantaleao L, de Sa BC et al. (2007) Alpha-v-beta3 integrin expression in mela-nocytic nevi and cutaneous melanoma. J Cutan Pathol 34:851-856
163. Nicholaou T, Ebert LM, Davis ID et al. (2009) Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMA-TRIX vaccine in patients with advanced malignant melanoma. Clin Cancer Res15:2166-2173
164. Niedojadlo K, Labedzka K, Lada E et al. (2006) Apaf-1 expression in human cutaneous melanoma progression and in pigmentednevi. Pigment Cell Res 19:43-50
165. Niezabitowski A, Czajecki K, Rys J et al. (1999) Prognostic evaluation of cutaneous malignant melanoma: a clinicopathologic and immunohistochemical study. J Surg Oncol 70:150-160
166. Nikkola J, Vihinen P, Vlaykova T et al. (2001) High collagenase-1 expression correlates with a favourable chemoimmunotherapy response in human metastatic melanoma. Melanoma Res 11:157-166
167. Nikkola J, Vihinen P, Vlaykova T et al. (2002) High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma. Int J Cancer 97:432-438
168. Ofori-Acquah SF, King JA (2008) Activated leukocyte cell adhesion molecule: a new paradox in cancer. Transl Res 151:122-128
169. Pecina-Slaus N, Zigmund M, Kusec V et al. (2007) E-cadherin and beta-catenin expression patterns in malignant melanoma assessed by image analysis. J Cutan Pathol 34:239-246
170. Perez-Pinera P, Berenson JR, Deuel TF (2008) Pleiotrophin, a multifunctional angiogenic factor: mechanisms and pathways in normal and pathological angiogenesis. Curr Opin Hematol 15:210-214
171. Persons DL, Arber DA, Sosman JA et al. (2000) Amplification and overexpression of HER-2/ neu are uncommon in advanced stage melanoma. Anticancer Res 20:1965-1968
172. Phan A, Touzet S, Dalle S et al. (2006) Acral lentiginous melanoma: a clinicoprognostic study of 126 cases. Br JDermatol 155:561-569
173. Pisacane AM, Picciotto F, Risio M (2007) CD31and CD34 expression as immunohistochem-ical markers of endothelial transdifferentia-tion in human cutaneous melanoma. Cell Oncol 29:59-66
174. Pisacane AM, Risio M (2005) VEGF and VEGFR-2 immunohistochemistry in human melanocy-tic naevi and cutaneous melanomas. Melanoma Res 15:39-43
175. Podhajcer OL, Bover L, Bravo AI et al. (1995) Expression of cathepsin D in primary and metastatic human melanoma and dysplastic nevi. J Invest Dermatol 104:340-344
176. Polak ME, Borthwick NJ, Gabriel FG et al. (2007) Mechanisms of local immunosuppression in cutaneous melanoma. Br J Cancer 96:1879-1887
177. Potti A, Hille R, Koch M (2003a) Immunohisto-chemical determination of HER-2/neu in malignant melanoma. Anticancer Res 23:4067-4069
178. Potti A, Moazzam N, Langness E et al. (2004) Immunohistochemical determination of HER-2/neu, c-Kit (CD117), and vascular endothelial growth factor (VEGF) overex-pression in malignant melanoma. J Cancer Res Clin Oncol 130:80-86
179. Potti A, Moazzam N, Tendulkar K et al. (2003b) Immunohistochemical determination of vascular endothelial growth factor (VEGF) over-expression in malignant melanoma. Anticancer Res 23:4023-4026
180. Poyraz A, Akyurek N, Gonul II et al. (2004) P21and Bax expression in cutaneous malignant melanomas: correlation with histologic prognostic parameters. J Exp Clin Cancer Res 23:625-631
181. Prieto VG, Mourad-Zeidan AA, Melnikova V et al. (2006) Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma. Clin Cancer Res 12:6709-6715
182. Pritchard-Jones RO, Dunn DB, Qiu Y, et al. (2007) Expression of VEGF(xxx)b, the inhibitory isoforms of VEGF, in malignant melanoma. Br J Cancer 97:223-230
183. Pryor JG, Bourne PA, Yang Q et al. (2008) IMP-3is a novel progression marker in malignant melanoma. Mod Pathol 21:431-7c
184. Quintela I, Vizoso F, Serra C et al. (2001) Immunohistochemical study of pepsinogen C expression in cutaneous malignant melanoma: association with clinicopathological parameters. Int J Biol Markers 16:240-244
185. Rangel J, Nosrati M, Leong SP, et al. (2008) Novel role for RGS1 in melanoma progression. AmJ Surg Pathol 32:1207-1212
186. Redondo P, Lloret P, Idoate M et al. (2005) Expression and serum levels of MMP-2 and MMP-9 during human melanoma progression. Clin Exp Dermatol 30:541-545
187. Redondo P, Sanchez-Carpintero I, Bauza A et al. (2003) Immunologic escape and angiogen-esis in human malignant melanoma. JAmAcad Dermatol 49:255-263
188. Ribatti D, Vacca A, Ria R et al. (2003) Neovascu-larisation, expression of fibroblast growth factor-2, and mast cells with tryptase activity increase simultaneously with pathological progression in human malignant melanoma. Eur J Cancer 39:666-674
189. Rothhammer T, Poser I, Soncin F et al. (2005) Bone morphogenic proteins are overex-pressed in malignant melanoma and promote cell invasion and migration. Cancer Res 65:448-456
190. Salven P, Heikkila P, Joensuu H (1997) Enhanced expression of vascular endothelial growth factor in metastatic melanoma. Br J Cancer 76:930-934 (Pubitemid 27401946)
191. Sanders DS, Blessing K, Hassan GA et al. (1999) Alterations in cadherin and catenin expression during the biological progression of melanocytic tumours. Mol Pathol 52:151-157
192. Sauane M, Su ZZ, Gupta P et al. (2008) Autocrine regulation of mda-7/IL-24 mediates cancer-specific apoptosis. Proc Natl Acad Sci USA 105:9763-9768
193. Schadendorf D, Gawlik C, Haney U, et al. (1993) Tumour progression and metastatic behaviour in vivo correlates with integrin expression on melanocytic tumours. J Pathol 170:429-434
194. Schadendorf D, Heidel J, Gawlik C, et al. (1995a) Association with clinical outcome of expression of VLA-4 in primary cutaneous malignant melanoma as well as P-selectin and E-selectin on intratumoral vessels. J Natl Cancer Inst 87:366-371
195. Schadendorf D, Jurgovsky K, Kohlmus CM et al. (1995b) Glutathione and related enzymes in tumor progression and metastases of human melanoma. J Invest Dermatol 105:109-112
196. Schmidt AN, Nanney LB, Boyd AS et al. (2006) Oestrogen receptor-beta expression in mel-anocytic lesions. Exp Dermatol 15:971-980
197. Schuierer MM, Bataille F, Hagan S et al. (2004) Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines. Cancer Res 64:5186-5192
198. Seidl H, Richtig E, Tilz H et al. (2007) Profiles of chemokine receptors in melanocytic lesions: de novo expression of CXCR6 in melanoma. Hum Pathol 38:768-780
199. Shen SS, Zhang PS, Eton O et al. (2003) Analysisof protein tyrosine kinase expression in melanocytic lesions by tissue array. J Cutan Pathol 30:539-547
200. Si Z, Hersey P (1994) Immunohistological examination of the relationship between meta-static potential and expression of adhesion molecules and selectins on melanoma cells. Pathology 26:6-15
201. Sienel W, Polzer B, Elshawi K et al. (2008) Cellular localization of EMMPRIN predicts prognosis of patients with operable lung adenocarcinoma independent from MMP-2 and MMP-9. Mod Pathol 21:1130-1138
202. Silye R, Karayiannakis AJ, Syrigos KN et al. (1998) E-cadherin/catenin complex in benign and malignant melanocytic lesions. J Pathol 186:350-355
203. Simonetti O, Goteri G, Lucarini G et al. (2006) Potential role of CCL27 and CCR10 expression in melanoma progression and immune escape. Eur J Cancer 42:1181-1187
204. Simonetti O, Lucarini G, Brancorsini D et al. (2002) Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metallopro-teinase 9 in cutaneous melanocytic lesions. Cancer 95:1963-1970
205. Singh RK, Varney ML, Bucana CD et al. (1999) Expression of interleukin-8 in primary and metastatic malignant melanoma of the skin. Melanoma Res 9:383-387
206. Slater M, Scolyer RA, Gidley-Baird A et al. (2003) Increased expression of apoptotic markers in melanoma. Melanoma Res 13:137-145
207. Slingluff CL Jr, Petroni GR, Olson W et al. (2008) Helper T-cell responses and clinical activity of a melanoma vaccine with multiple pep-tides from MAGE and melanocytic differentiation antigens. J Clin Oncol 26:4973-4980
208. Slipicevic A, Jorgensen K, Skrede M et al. (2008) The fatty acid binding protein 7 (FABP7) is involved in proliferation and invasion of melanoma cells. BMC Cancer 8:276
209. Sotiriou C, Pusztai L (2009) Gene-expression signatures in breast cancer. N Engl J Med 360:790-800
210. Spinella F, Rosano L, Di Castro V et al. (2007) Endothelin-1 and endothelin-3 promote invasive behavior via hypoxia-inducible fac-tor-1alpha in human melanoma cells. Cancer Res 67:1725-1734
211. Stefanou D, Batistatou A, Zioga A et al. (2004) Immunohistochemical expression of vascular endothelial growth factor (VEGF) and C-KIT in cutaneous melanocytic lesions. Int J Surg Pathol 12:133-138
212. Straume O, Akslen LA (2001) Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. Am JPathol 159:223-235
213. Straume O, Akslen LA (2002) Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angio-genic factors basic fibroblast growth factor/ fibroblast growth factor receptor-1 and ephrin-A1/EphA2 on melanoma progression. Am J Pathol 160:1009-1019
214. Strebhardt K, Kneisel L, Linhart C et al. (2000) Prognostic value of pololike kinase expression in melanomas. JAMA 283:479-480
215. Tan H, Ye K, Wang Z et al. (2008) Clinicopatho-logic evaluation of immunohistochemical CD147 and MMP-2 expression in differentiated thyroid carcinoma. Jpn J Clin Oncol 38:528-533
216. Tang L, Su M, Zhang Y et al. (2008) Endothelin-3 is produced by metastatic melanoma cells and promotes melanoma cell survival. J Cutan Med Surg 12:64-70
217. Tang L, Tron VA, Reed JC et al. (1998) Expression of apoptosis regulators in cutaneous malignant melanoma. Clin Cancer Res 4:1865-1871
218. Taylor C (2006) Standardization in immunohis-tochemistry: the role of antigen retrieval in molecular morphology. Biotech Histochem 81:3-12
219. Torlakovic EE, Bilalovic N, Nesland JM et al. (2004) Ets-1 transcription factor is widely expressed in benign and malignant melano-cytes and its expression has no significant association with prognosis. Mod Pathol 17:1400-1406
220. Tsao H, Atkins MB, Sober AJ (2004) Management of cutaneous melanoma. N Engl J Med 351:998-1012
221. Tucci MG, Lucarini G, Brancorsini D et al. (2007) Involvement of E-cadherin, beta-catenin, Cdc42 and CXCR4 in the progression and prognosis of cutaneous melanoma. Br J Dermatol 157:1212-1216
222. Vacca A, Ribatti D, Roncali L et al. (1993) Melanocyte tumor progression is associated with changes in angiogenesis and expression of the 67-kilodalton laminin receptor. Cancer 72:455-461
223. Van Belle P, Rodeck U, Nuamah I et al. (1996) Melanoma-associated expression of transforming growth factor-beta isoforms. Am J Pathol 148:1887-1894
224. Van Belle PA, Elenitsas R, Satyamoorthy K et al. (1999) Progression-related expression of beta3 integrin in melanomas and nevi. Hum Pathol 30:562-567
225. van den Oord JJ, Paemen L, Opdenakker G et al. (1997) Expression of gelatinase B and the extracellular matrix metalloproteinase indu-cer EMMPRIN in benign and malignant pigment cell lesions of the skin. Am J Pathol 151:665-670
226. van Kempen LC, van den Oord JJ, van Muijen GN et al. (2000) Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin. Am J Pathol 156:769-774
227. van Kilsdonk JW, Wilting RH, Bergers M et al. (2008) Attenuation of melanoma invasion by a secreted variant of activated leukocyte cell adhesion molecule. Cancer Res 68: 3671-3679
228. Varney ML, Johansson SL, Singh RK (2005) Tumour-associated macrophage infiltration, neovascularization and aggressiveness in malignant melanoma: role of monocyte chemotactic protein-1 and vascular endothe-lial growth factor-A. Melanoma Res 15:417-425
229. Varney ML, Johansson SL, Singh RK (2006) Distinct expression of CXCL8 and its receptors CXCR1 and CXCR2 and their association with vessel density and aggressiveness in malignant melanoma. Am J Clin Pathol 125:209-216
230. Velazquez EF, Jungbluth AA, Yancovitz M et al. (2007a) Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)-correlation with prognostic factors. Cancer Immun 7:11
231. Velazquez EF, Yancovitz M, Pavlick A et al. (2007b) Clinical relevance of neutral endo-peptidase (NEP/CD10) in melanoma. JTransl Med 5:2
232. Vereecken P, Debray C, Petein M et al. (2005) Expression of galectin-3 in primary and metastatic melanoma: immunohistochem-ical studies on human lesions and nude mice xenograft tumors. Arch Dermatol Res 296:353-358
233. Vlaykova T, Laurila P, Muhonen T et al. (1999) Prognostic value of tumour vascularity in metastatic melanoma and association of blood vessel density with vascular endothe-lial growth factor expression. Melanoma Res 9:59-68
234. Voigt H, Houben R, Schrama D et al. (2007) Matrix metalloproteinase induction in the tumor stroma does not depend on CD147 expression in murine B16 melanoma. Tumour Biol 28:229-237
235. Voigt H, Vetter-Kauczok CS, Schrama D et al. (2009) CD147 impacts angiogenesis and metastasis formation. Cancer Invest 27:329-333
236. von Schoultz E, Carlstrom K, Henriksson R et al. (1994) Estramustine binding protein in primary tumours and metastases of malignant melanoma. Melanoma Res 4:401-405
237. Wang H, Shen SS, Wang H et al. (2003) Expression of insulin-like growth factor-binding protein 2 in melanocytic lesions. J Cutan Pathol 30:599-605
238. Wang Y, Dai DL, Martinka M et al. (2007) Prognostic significance of nuclear ING3 expression in human cutaneous melanoma. Clin Cancer Res 13:4111-4116
239. Weishaupt C, Munoz KN, Buzney E et al. (2007) T-cell distribution and adhesion receptor expression in metastatic melanoma. Clin Cancer Res 13:2549-2556
240. Weiss J, Biwer B, Schliz M et al. (1997) Clinicopathological and prognostic relevance of Rap1-GAP expression in melano-cytic tumors. Arch Dermatol Res 289: 573-577
241. Winnepenninckx V, Debiec-Rychter M, Belien JA et al. (2006a) Expression and possible role of hPTTG1/securin in cutaneous malignant melanoma. Mod Pathol 19: 1170-1180
242. Winnepenninckx V, Lazar V, Michiels S et al. (2006b) Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 98:472-482
243. Witze ES, Litman ES, Argast GM, et al.(2008) Wnt5a control of cell polarity and directional movement by polarized redistribution of adhesion receptors. Science 320:365-369
244. Wollina U, Kilian U, Henkel U et al. (1991) The initial steps of tumor progression in melano-cytic lineage: a histochemical approach. Anticancer Res 11:1405-1414
245. Wong RP, Khosravi S, Martinka M et al. (2008) Myeloid leukemia-1 expression in benign and malignant melanocytic lesions. Oncol Rep 19:933-937
246. Woodward JK, ElshawSR, Murray AK, et al. (2002) Stimulation and inhibition of uveal melanoma invasion by HGF, GRO, IL-1alpha and TGF-beta. Invest Ophthalmol Vis Sci 43:3144-3152
247. Wu H, Barusevicius A, Babb J et al. (2005) Pleiotrophin expression correlates with mel-anocytic tumor progression and metastatic potential. J Cutan Pathol 32:125-130
248. Xerri L, Battyani Z, GrobJJ, et al. (1996) Expression of FGF1 and FGFR1 in human melanoma tissues. Melanoma Res 6:223-230
249. Yang YJ, Chen DZ, Li LX et al. (2009) Targeted IL-24 gene therapy inhibits cancer recur-rence after liver tumor resection by inducing tumor cell apoptosis in nude mice. Hepato-biliary Pancreat Dis Int 8:174-178
250. Yu JZ, Warycha MA, Christos PJ et al. (2008) Assessing the clinical utility of measuring insulin-like growth factor binding proteins in tissues and sera of melanoma patients. J Transl Med 6:70
251. Zhang XD, Hersey P (1999) Expression of catenins and p120cas in melanocytic nevi and cutaneous melanoma: deficient alpha-cate-nin expression is associated with melanoma progression. Pathology 31:239-246
252. Zhao J, Qi Q, Yang Y et al. (2008) Inhibition of alpha(4) integrin mediated adhesion was involved in the reduction of B16-F10 melanoma cells lung colonization in C57BL/6 mice treated with gambogic acid. Eur J Pharmacol 589:127-131
253. Zheng M, Bocangel D, Ramesh R et al. (2008) Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells. Mol Cancer Ther 7:3842-3851
254. Zhuang L, Lee CS, Scolyer RA et al. (2005) Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma. J Clin Pathol 58:1163-1169
255. Zhuang L, Lee CS, Scolyer RA et al. (2007) Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Mod Pathol 20:416-426
256. Zubieta MR, Furman D, Barrio M et al. (2006) Galectin-3 expression correlates with apop-tosis of tumor-associated lymphocytes in human melanoma biopsies. Am J Pathol 168:1666-1675
257. Zygouris P, Tsiambas E, Tiniakos D et al. (2007) Evaluation of combined h-TERT, bcl-2, and caspases 3 and 8 expression in cutaneous malignant melanoma based on tissue micro-arrays and computerized image analysis. J Buon 12:513-519